Hetzel H, Bichler A, Fuchs D, Hausen A, Reibnegger G, Wachter H
Cancer Detect Prev. 1983;6(1-2):263-6.
In patients with genital cancer (N = 108) significantly higher mean neopterine levels were found than in a healthy control group. Prior to therapy elevated neopterine levels were seen in 60% of the patients with cancer of the genitals varying between 90% (ovarian cancer) and 54% (cervical cancer). Nine patients with ovarian cancer (stages IIb-IV) were followed for a period of 16 months to date. All patients had elevated neopterine values prior to therapy. When the urinary neopterine excretion remained increased over the period of observation, progression of the tumor occurred within a few months. In patients with complete or partial remission of the tumor, the neopterine excretion dropped to normal values. Thus, we feel that neopterine sampling may be helpful in the follow-up of patients with ovarian cancer, as tumor progression is indicated very early, before clinicoroentgenological findings are present.
在患有生殖系统癌症的患者（N = 108）中，发现其平均新蝶呤水平显著高于健康对照组。在治疗前，60%的生殖器癌症患者新蝶呤水平升高，其中卵巢癌患者的比例为90%，宫颈癌患者为54%。截至目前，对9例IIb-IV期卵巢癌患者进行了为期16个月的随访。所有患者在治疗前新蝶呤值均升高。在观察期内，若尿新蝶呤排泄持续增加，则肿瘤会在数月内进展。肿瘤完全或部分缓解的患者，新蝶呤排泄降至正常水平。因此，我们认为新蝶呤采样可能有助于卵巢癌患者的随访，因为在临床放射学检查结果出现之前，肿瘤进展就能很早被发现。
